MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,EGFR	SA00043350	15	F	SA00043350
Ordering Phys				**DOB** 06/10/1996
Client Order # SA00043350	**Account Information**			**Report Notes**
Collected 02/08/2012 13:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 02/10/2012 10:02				

Test	Flag	Results	Unit	Reference Value	Perform Site*
EGFR Gene, Mutation Analysis, Tumor			REPORTED 02/09/2012 14:14		
Specimen		Tissue			MCR
Specimen ID		1037731			MCR
Order Date		09 Feb 2012 14:02			MCR
Reason for Referral					MCR

Evaluate tumor DNA for presence of a mutation in exons 18-21 of the EGFR gene.

Method MCR

A PCR based assay employing allele specific amplification was used to test for the presence of 29 mutations within exons 18-21 of the EGFR gene (G719A, G719S, G719C in exon 18; small deletions in exon 19; T790M, S768I, and small insertions in exon 20; and L858R and L861Q in exon 21). Mutation nomenclature is based on GenBank accession number; NM005228.3.

Result MCR

Tumor type: Non-small cell lung cancer
EGFR status: Mutant: A deletion was detected in exon 19

Interpretation MCR

Current data suggests that patients with non-small cell lung cancer with mutations in the tyrosine kinase domain (exons 18-21) of EGFR may respond to EGFR-tyrosine kinase inhibitor therapies. Therefore, the detection of an EGFR mutation within this tumor specimen suggests that this patient may respond to such therapies.

The predictive value of EGFR testing applies to EGFR-tyrosine kinase inhibitor therapies, not to other therapeutic agents. Additionally, please note that not all patients that have mutant EGFR tumors respond to EGFR-tyrosine kinase inhibitor therapies.

It is estimated that this panel detects greater than 95% of pathogenic mutations in exons 18-21 of the EGFR gene.

Consideration of these results, in light of other clinical information, may aid in clinical management decisions for this patient.

CAUTIONS:
Rare polymorphisms exist that could lead to false negative or false positive results. Test results should be interpreted in context of clinical findings, tumor sampling, and other laboratory data. If results obtained do not match

Performing Site Legend on Last Page of Report

* Report times for Mayo performed tests are CST/CDT

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,EGFR	SA00043350	15	F	SA00043350
Ordering Phys				**DOB** 06/10/1996
Client Order # SA00043350	**Account Information**			**Report Notes**
Collected 02/08/2012 13:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 02/10/2012 10:02				

Test	Flag	Results	Unit	Reference Value	Perform Site*
other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.					
For research use only.					
Reviewed By:		Benjamin Robert Kipp			MCR
Release Date		09 Feb 2012 14:12			MCR

* Performing Site:

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

TEST SITE